Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/2/2008

nts studied in ATHENA were either 75 years of age or older (with or without cardiovascular risk factor) or above 70 years of age with at least one additional cardiovascular risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40%). Patients were randomized to receive Multaq(R) 400 mg BID or placebo, with a maximum follow-up of 30 months.

The ATHENA study objectives were to show a potential benefit of Multaq(R) on the primary composite endpoint of all-cause mortality combined with cardiovascular hospitalization as compared to placebo. The pre-specified secondary endpoints were death from any cause, cardiovascular death and hospitalisation for cardiovascular reasons. The pre-specified safety endpoint was the incidence of treatment emergent adverse events (between first study drug intake and last study drug intake plus 10 days) including: all adverse events, serious adverse events, adverse events leading to study drug discontinuation.

The ATHENA stroke post-hoc analysis on a non-pre-specified secondary endpoint was conducted in order to confirm the consistent benefit of Multaq(R) in atrial fibrillation or atrial flutter patients in reducing major cardiovascular complications like stroke, which is a leading cause of cardiovascular hospitalizations or death in this patient population.

About Multaq(R) (dronedarone)

Multaq(R) is an investigational treatment and the only anti-arrhythmic drug (AAD) to have shown a significant reduction in morbidity and mortality in atrial fibrillation /atrial flutter patients with a favourable safety profile as evidenced by a low incidence of pro-arrhythmia (including torsades de pointes) and extra-cardiac organ toxicity.

Multaq(R), discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 7,000 patients. Multaq(R) is one of the major therapeutic innov
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
2. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
3. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
4. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
5. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
6. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
7. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
8. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
9. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
10. Arpida Provides Further Comments on the Pivotal Phase III Trials
11. Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CARLSBAD, Calif. , May 23, 2013 Isis ... antisense therapeutics, today announced that management will present a company ... Health Care Conference on Thursday, May 30, 2013 at 8:40 ... A live audio webcast of the presentation will be ... Web site, www.isispharm.com .  A replay will be available ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, Inc., ... today that it will present new results on ... industry conference sponsored by the PML Consortium (composed ... JC polyomavirus (JCV) is the causative agent of ... kinase inhibitor in an extended release formulation, can ...
(Date:5/23/2013)... NEW YORK , May 23, 2013  Echo ... has committed to waive down the Acceptance Threshold from ... Affected plus one Elan Share in accordance with the ... to the conditions summarized below. Under the ... to acquire Elan (NYSE: ELN ) for ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
(Date:5/23/2013)... York, New York (PRWEB) May 23, 2013 ... manufactured by C.R. Bard, Inc., continue to move forward ... Court, Southern District of West Virginia, Bernstein Liebhard LLP ... the Court denied a request by C.R. Bard to ... would reveal trade secrets and other confidential, proprietary information ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
(Date:5/23/2013)... May 23, 2013 Former United States ... for Acadian 's annual Paramedic Luncheon. , ... Convention Center, Cheney praised Acadian's medics, saying, "I am ... participate in awarding the Paramedic of the Year Award. ... is a lot of competition within a company like ...
(Date:5/23/2013)... The vast majority of Americans believe it’s possible ... level of physical activity, the healthfulness of their diet ... that control. Those are among the findings of ... & Health Survey. , According to the Survey, 90 ... great deal of control” or “complete control” over their ...
Breaking Medicine News(10 mins):Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4
... from UK show that proteins secreted by eggs of the ... the next anti-inflammatory therapy // . ,Their study ... Experimental Medicine. ,Schistosoma mansoni, a trematode parasite that ... the host to tolerate chronic worm infections, often for decades, ...
... many different forms of cancer. Smoking is linked to many ... For example, 1/3rd of all bladder cancers are caused due ... the scientific community to sensitize individuals to the ill effects ... ,A new study conducted on cancer patients has ...
... been widely talked about and largely accepted. In the same ... there is a 15% reduction in the risk of heart ... of three months. , ,The sample size was 212 ... disease were put to eat a Mediterranean diet for three ...
... having IVF treatment subject themselves to more risks and complications ... fertilization (IVF) has been very successful in women who are ... the procedure a donated egg and a sperm is fertilized ... the womb of a woman. The egg can sometimes be ...
... due to Peanut allergy after her boyfriend kissed her after ... city of Saguenay, though she received a dose of adrenaline ... the hypersensitivity reaction and died a week after the kiss. ... an autopsy has been planned for Christina Desforges. , ...
... The Scientific Advisory Committee for Nutrition in United Kingdom ... acid/Vitamin B12.// , Folic acid acts as an ... women has it protects newborn babies from birth defects. ... people as they are prone to B12 deficiency leading ...
Cached Medicine News:Health News:Most Smokers Continue To Smoke Despite Developing Cancer 2Health News:Complication More in Women Having IVF Treatment 2
A rapid, convenient, qualitative method for detecting asymptomatic occult bleeding....
... The use of guaiac as a test ... the oxidation of phenolic compounds present in guaiac ... blue color. If blood is present, the heme ... a pseudoenzymatic manner, catalyzing the release of oxygen ...
... The Original MaybeMom™ Mini ... medical diagnostic instument which uses ... her personal menstrual/fertility cycle, including ... ovulation and menstruation to increase ...
... only test designed specifically for detecting ... pH. It includes a convenient pH ... range which is important in monitoring ... can now spend less time testing ...
Medicine Products: